Seattle Prostate Institute, an affiliate of Swedish Cancer Institute, is offering free prostate cancer screening tests on Fri., Nov. 20 between 8 a.m. and 3:30 p.m. at their offices in the 1101 Madison Medical Tower, Suite 1101, on the Swedish/First Hill Campus.

The American Society for Radiation Oncology (ASTRO) will host news briefings with accompanying live webcasts on the top cancer research papers from its 51st Annual Meeting to be held this coming week in Chicago. Prostate cancer features in three of briefings. We’ll bring these stories when we have them, here are the headlines:

News briefing 1:
Monday, November 2, at 8:00 a.m. (Central); 9:00 a.m. (Eastern)
Study findings previewed:
Four months hormone therapy added to radiation increases survival for medium-risk, but not low-risk, prostate cancer patients (late-breaking study).

The Obama administration has changed Federal policies on regulation of medical marijuana use under state law. During his presidential race last year, Barack Obama said that he intended to halt raids of medical marijuana facilities operating legally under state laws. Today, new Justice Department guidelines brought this change about.

The new guidelines order federal drug agents to stop arresting or charging patients, caregivers or suppliers who are dispensing, buying or using marijuana for medical purposes allowed by state law.

All over the internet people are receiving and passing on messages starting out with words like this:

Received this excellent advice regarding H1N1/Swine Flu from . . .

The blog post or email forwards a message that starts out:

Subject: Possible swine flu prevention
This message is from Dr. Vinay Goyal a renowned doctor who visited last week to lecture on the topic H1N1 (SWINE FLU), its origin and precautions. He is an MBBS,DRM,DNB (Intensivist and Thyroid specialist) having clinical experience of more than 20 years. He has worked in institutions like Hinduja Hospital, Bombay Hospital, Saifee Hospital, Tata Memorial etc. Presently, he is heading our Nuclear Medicine Department and Thyroid clinic at Riddhivinayak Cardiac and Critical Centre, Malad (W).

Gavin Rodden, the 8 year boy fighting metastatic muscle cancer called rhabdomyosarcoma, which began in muscle in his prostate, now has a web page at CaringBridge, Gavin the Strong:

http://www.caringbridge.org/visit/gavinthestrong

Gavin is taking chemotherapy in Houston. To donate to the Medical Fund that Shannon’s employer has set up for Gavin (see details in our previous post) send a check, in any amount, payable to Gavin Rodden Medical Fund and mail to:
Citizens’ National Bank
PO Box 1009
Henderson
TX 75653-1009
To validate the address and the fund you may contact the bank from this page: https://www.cnbtexas.com/#/contact-us
Or donate to “Gavin Rodden’s Hospital Fund” via PayPal.

Eight-year-old Gavin Rodden was diagnosed recently with a rare childhood cancer, which began in his prostate.

Rhabdomyosarcoma (Rhab-do-my-o-sarcoma) is an aggressive form of cancer that starts in a muscle cell and may spread quite rapidly. In Gavin’s case the cancer has already spread from the prostate to his lungs. Possible treatments include surgery, radiation therapy, chemotherapy and options in clinical trials.

This little boy is facing challenges that any man might find overwhelming.

We feel some guys might like to add some big brother outreach to back up the support Gavin is already receiving from East Texans.

Reuters and WAll Street Journal report today that Dendreon plans to seek US FDA approval for Provenge prostate cancer vaccine in November. Dendreon “expects regulators to act on the application by the middle of next year, the company said on Thursday.”

To start from an updated report in the Wall Street Journal, which adds this information to Reuters’ coverage of Dendreon ’s share prices today. The points are excerpted and reordered:

Scientists have identified seven new genetic variants that appear to be linked with increase risk of prostate cancer. Among these are four new “single-letter” genetic variants on one particular chromosome, called 8q24.

This chromosomal region has previously been associated with breast, colon, and bladder cancer. The discoveries identifying the four new genetic locations associated with prostate cancer on chromosome 8q24 were made by teams of independent scientists around the world. Three separate research papers on the discoveries are published in the online issue of Nature Genetics.

In one of the papers, Rosalind Eeles, from the London, UK Institute of Cancer Research laboratory (ICR) and colleagues in the Genetic Epidemiology Unit, University of Cambridge, report on the discovery of seven new prostate cancer susceptibility loci. In this video Dr. Eeles explains what her team found. She says they plan to take the results “into the clinic” to try to predict which men may need early testing for prostate cancer. Dr. Eeles says 8q is a “very interesting part of the genome for solid cancer risk.”

Brave New Films’ video Sick for Profit opens with a clip of a woman, Jo Joshua Godfrey, who says Cigna cut off her coverage by telling her she had nothing wrong with her, when they knew — as she did not — that her scans showed she had lung cancer.

I would go to CIGNA and they would tell me I had bronchitis and give me medicine and send me home. Then the CIGNA Director called me up and she told me that there was nothing wrong with me at all. I called the doctor, and I came with my film and my CAT scan and he just put it in, it took exactly thirty seconds. He told me, ‘You have cancer,’ and he said the reason CIGNA did not want to give you your records is they’ve known right way back for years that you have cancer and they’re not going to treat you.” Jo Joshua Godfrey.

the 4th C2 Academic Retreat (C2R) being organized jointly by the Canadian Urologic Oncology Group (CUOG) and the Canadian Urology Research Consortium (CURC) is scheduled for the weekend of September 25 to 27, 2009 at the fashionable hotel called W in Montreal.

According to UroToday, “this three-day educational event will include provocative ‘Town Hall’ sessions on the topics of Hormone Replacement and Cancer Risk, Prostrate Screening Controversies and the use of Robotic Technology in Surgery (Is it ready for prime time?).” “The line-up of topics and the caliber of presenters is unsurpassed in all the years we have been conducting these events,” says Dr. Laurence Klotz, Chair of the CURC and immediate past president of the Canadian Urology Association (CUA).

The Retreat allows the sponsoring (and often competing) pharmaceutical companies (i.e. Amgen AstraZeneca, Sanofi Aventis, GlaxoSmitKline, Merck Frosst, Novartis, Minoque Medical, Genesis Genomics, and Pfizer) to actively participate in the academic portion of the agenda.